Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-530-6 | CAS number: 29240-17-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Date: September 25, 1981
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: Conducted in accordance with the regulations for Good Laboratory Practices as described by the FDA (21 CFR Part 58) and FDRL Standard Operating Procedures
- Principles of method if other than guideline:
- Animals were individually housed in wire mesh bottom cages in environment controlled rooms as per "Guide for the care and Use of Laboratory Animals" DREW, Publication No. (NIH) 78-23.
Animals were fasted overnight (approximately 18 hours) prior to receiving a single oral dose of the test article. - GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- tert-pentyl peroxypivalate
- EC Number:
- 249-530-6
- EC Name:
- tert-pentyl peroxypivalate
- Cas Number:
- 29240-17-3
- Molecular formula:
- C10H20O3
- IUPAC Name:
- tert-pentyl peroxypivalate
- Reference substance name:
- Hydrocarbons, C4, 1,3-butadiene-free, polymd., triisobutylene fraction, hydrogenated
- EC Number:
- 297-629-8
- EC Name:
- Hydrocarbons, C4, 1,3-butadiene-free, polymd., triisobutylene fraction, hydrogenated
- Cas Number:
- 93685-81-5
- Molecular formula:
- not applicable (a generic molecular formula cannot be provided for this specific UVCB substance)
- IUPAC Name:
- isododecane
- Test material form:
- liquid
Constituent 1
additive 1
- Specific details on test material used for the study:
- FDRL Test Article ID: 81-0558
Sponsor Test Article ID: TA-54M75; tert-amyl peroxypivalate 75% in odorless mineral spirit
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- A sufficient number of young adult male and female Sprague-Dawley rats were purchased from Charles River Breeding Laboratories, Wilmington, MA. After an acclimation period of approximately 3 - 5 days , the animals were assigned to groups of one male and one female at five dose levels for the preliminary study, and a sufficient number of males and females at five dose levels for the principal study.
Animals were individually housed in wire mesh bottom cage s in environment controlled rooms as per "Guide for the Care and Use of Laboratory Animals" DHEW Publication No. (NIH) 78-23.
Animals were fasted overnight (approximately 18 hours) prior to receiving a single oral dose of the test article.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- Preliminary:
1.0, 1.5, 2.24, 3.34 and 5.0 mg/kg.
Main:
3.0, 3.41, 3.87, 4.40 and 5.0 mg/kg - No. of animals per sex per dose:
- Preliminary
1 male and 1 female per dose.
Main
5 males and 5 females per dose. - Control animals:
- not specified
- Details on study design:
- Observations
All animals on the main study were observed for 15 days. They were observed three times on the day of dosing, twice on the fol lowing day and once daily for the remainder of the study. All gross or visible toxic or pharmacological effects were recorded. Body weights were recorded initially and on day 15 or at death.
Sacrifice and Necropsy
All animals that died during the study were subjected to a gross necropsy. All abnormalities were recorded.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 4 270 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 3.85 - <= 5.18
- Remarks on result:
- other: 4.27 g/kg bw
- Mortality:
- Preliminary:
Mortality = 2/2 at 5.0 mg/kg
Main:
Mortality at: 3.0 mg/kg = 1/10
3.41 mg/kg = 3/10
3.87 mg/kg = 2/10
4.40 mg/kg = 5/10
5.0 mg/kg = 8/10 - Clinical signs:
- other: See table in "Any Other Information on Results"
- Gross pathology:
- See table in "Any Other Information on Results"
Any other information on results incl. tables
Preliminary search
Dosage level (g/kg) | 1.0 | 1.5 | 2.24 | 3.34 | 5.0 |
Mortality after 7 days | 0/2 | 0/2 | 0/2 | 0/2 | 2/2 |
Two rats per dosage level
LD50Assay
Dosage Level g/kg | Time of Death | Cumulative Mortality | ||||||||||||||
Day | ||||||||||||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | ||
3.0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1/10 |
3.41 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3/10 |
3.87 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2/10 |
4.40 | 0 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5/10 |
5.0 | 1 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8/10 |
Ten rats (5 male and 5 female) per dosage level.
Mean Body weight data
Sex and Dosage Level g/kg | Initial (grams) | Day 15 (grams) | At Death (grams) | |
Male | 3.0 | 243.4 ± 7.8 (5) | 307.6 ± 12.3 (5) | - |
3.41 | 248.6 ± 16.8 (5) | 325.2 ± 20.1 (5) | - | |
3.87 | 288.6 ± 37.1 (5) | 347.6 ± 42.9 (5) | - | |
4.40 | 287.6 ± 22.5 (5) | 341.2 ± 27.0 (5) | - | |
5.0 | 284.8 ± 30.6 (5) | 366.0 (1) | 252.8 ± 41.1 (4) | |
Female | 3.0 | 230.8 ± 7.0 (5) | 267.0 ± 8.1 (4) | 186.0 (1) |
3.41 | 216.8 ± 21.5 (5) | 261.0 ± 55.2 (2) | 201.3 ± 11.1 (3) | |
3.87 | 203.8 ± 10.8 (5) | 242.7 ± 22.0 (3) | 164.5 ± 9.2 (2) | |
4.40 | 198.8 ± 12.1 (5) | - | 181.6 ± 10.9 (5) | |
5.0 | 211.0 ± 11.9 (5) | 242.0 (1) | 194.5 ± 13.2 (4) |
Summary of observations
Dosage Level g/kg | Clinical Observations | Necropsy Observations |
2.0 | Decreased activity (5M & 5F), Salivation (3M & 3F) , Ataxia (5M & 5F) , Diarrhoea (4M & 3F) , Urinary incontinence (1M & 3F), Deaths (1F) | Intestines: contain blood like viscous liquid (1F) . |
3.41 | Decreased activity (5M & 5F), Ataxia (5M & 5F), Diarrhoea (3M & 4F), Deaths (3F). | Intestines: contain blood like viscous liquid (1F) . |
3.87 | Decreased activity (5M & 5F), Ataxia (5M & 5F) , Diarrhoea (3M & 5F), Rectal area red in color (3M & 5F), Urinary incontinence (3M & 4F), Salivation (2M & 2F), Deaths (2F). | Intestines: contain blood like viscous liquid (2F). |
4.40 | Decreased ac tivity (5M & 5F), Ataxia (5M & 5F), Diarrhoea (3M & 3F), Salivation (2M & 2F), Lacrimation (4F), Deaths (5F) . | Intestines: contain bloodlike viscous liquid (3F). Bladder: contains bloodlike liquid (2F). |
5.0 | Decreased activity (5M & 5F), Ataxia (5M & 5F), Diarrhoea (4M & 5F), Urinary incontinence (4M & 1F), Rectal area red in color (3M & 3F), Lacrimation (3M & 1F), Deaths (4M & 4F) . | Intestines: contain bloodlike viscous liquid (3F). |
Applicant's summary and conclusion
- Interpretation of results:
- Category 5 based on GHS criteria
- Conclusions:
- The oral LD50 is 4270 mg/kg. This warrants classification in category 5 according to GHS criteria (table 3.1.1 note g-ii).
- Executive summary:
Acute Oral LD50 (g /kg): 4.27
95% Confidence Intervals: 3.85 - 5.18
Slope: 8.58
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
